Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 768

1.

An International Analysis of Dialysis Services Reimbursement.

van der Tol A, Lameire N, Morton RL, Van Biesen W, Vanholder R.

Clin J Am Soc Nephrol. 2018 Dec 13. pii: CJN.08150718. doi: 10.2215/CJN.08150718. [Epub ahead of print]

PMID:
30545819
2.

Subclinical AKI: ready for primetime in clinical practice?

Vanmassenhove J, Van Biesen W, Vanholder R, Lameire N.

J Nephrol. 2018 Dec 6. doi: 10.1007/s40620-018-00566-y. [Epub ahead of print] Review.

PMID:
30523562
3.

Author Correction: Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec 11. doi: 10.1038/s41581-018-0099-y. [Epub ahead of print]

PMID:
30538326
4.

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Joossens M, Faust K, Gryp T, Nguyen ATL, Wang J, Eloot S, Schepers E, Dhondt A, Pletinck A, Vieira-Silva S, Falony G, Vaneechoutte M, Vanholder R, Van Biesen W, Huys GRB, Raes J, Glorieux G.

Gut. 2018 Nov 21. pii: gutjnl-2018-317561. doi: 10.1136/gutjnl-2018-317561. [Epub ahead of print] No abstract available.

5.

Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Review. Erratum in: Nat Rev Nephrol. 2018 Dec 11;:.

PMID:
30361677
6.

Treating potassium disturbances: kill the killers but avoid overkill.

Vanholder R, Van Biesen W, Nagler EV.

Acta Clin Belg. 2018 Oct 24:1-14. doi: 10.1080/17843286.2018.1531206. [Epub ahead of print]

PMID:
30353786
7.

Introduction to the Toxins Special Issue on "Novel Issues in Uremic Toxicity".

Vanholder R.

Toxins (Basel). 2018 Sep 25;10(10). pii: E388. doi: 10.3390/toxins10100388. No abstract available.

8.

Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?

Vanholder R, Glorieux G.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1311-1313. doi: 10.2215/CJN.08200718. Epub 2018 Aug 7. No abstract available.

PMID:
30087101
9.

Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study.

Karaboyas A, Morgenstern H, Pisoni RL, Zee J, Vanholder R, Jacobson SH, Inaba M, Loram LC, Port FK, Robinson BM.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2234-2244. doi: 10.1093/ndt/gfy190.

10.

Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.

Nagler EV, Haller MC, Van Biesen W, Vanholder R, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2018 Jun 28;6:CD010965. doi: 10.1002/14651858.CD010965.pub2. Review.

PMID:
29953167
11.

Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Vanholder R, Van Laecke S, Glorieux G, Verbeke F, Castillo-Rodriguez E, Ortiz A.

Toxins (Basel). 2018 Jun 12;10(6). pii: E237. doi: 10.3390/toxins10060237. Review.

12.

Haste makes waste-Should current guideline recommendations for initiation of renal replacement therapy for acute kidney injury be changed?

Vanmassenhove J, Vanholder R, Van Biesen W, Lameire N.

Semin Dial. 2018 May;31(3):204-208. doi: 10.1111/sdi.12693. Epub 2018 Apr 10.

PMID:
29635792
13.

Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.

Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2156-2164. doi: 10.1093/ndt/gfy020.

PMID:
29554320
14.

A plea for more uremic toxin research in children with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Vanholder R, Vande Walle J, Eloot S.

Pediatr Nephrol. 2018 Jun;33(6):921-924. doi: 10.1007/s00467-018-3920-8. Epub 2018 Mar 2. No abstract available.

PMID:
29500629
15.

Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access.

Viecelli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators.

Am J Kidney Dis. 2018 May;71(5):690-700. doi: 10.1053/j.ajkd.2017.12.003. Epub 2018 Feb 23.

PMID:
29478866
16.

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Vanholder R, Pletinck A, Schepers E, Glorieux G.

Toxins (Basel). 2018 Jan 8;10(1). pii: E33. doi: 10.3390/toxins10010033. Review.

17.

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.

Harris T, Sandford R, de Coninck B, Devuyst O, Drenth JPH, Ecder T, Kent A, Gansevoort RT, Górriz JL, Ong ACM, Pirson Y, Torres VE, Budde K, Clément D, Derchi LE, Eleftheroudi M, Levtchenko E, Peters D, Van Poppel H, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 22. doi: 10.1093/ndt/gfx327. [Epub ahead of print]

18.

Caring for Migrants and Refugees With End-Stage Kidney Disease in Europe.

Van Biesen W, Vanholder R, Ernandez T, Drewniak D, Luyckx V.

Am J Kidney Dis. 2018 May;71(5):701-709. doi: 10.1053/j.ajkd.2017.10.015. Epub 2017 Dec 21.

PMID:
29274918
19.

Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review.

Viecelli AK, O'Lone E, Sautenet B, Craig JC, Tong A, Chemla E, Hooi LS, Lee T, Lok C, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Irish AB, Mori TA, Pascoe EM, Johnson DW, Hawley CM.

Am J Kidney Dis. 2018 Mar;71(3):382-391. doi: 10.1053/j.ajkd.2017.09.018. Epub 2017 Dec 6.

PMID:
29203125
20.

Points of Concern in Post Acute Kidney Injury Management.

Vanmassenhove J, Vanholder R, Lameire N.

Nephron. 2018;138(2):92-103. doi: 10.1159/000484146. Epub 2017 Nov 2.

21.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

22.

Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS.

Locatelli F, Karaboyas A, Pisoni RL, Robinson BM, Fort J, Vanholder R, Rayner HC, Kleophas W, Jacobson SH, Combe C, Port FK, Tentori F.

Nephrol Dial Transplant. 2017 Oct 11. doi: 10.1093/ndt/gfx277. [Epub ahead of print]

23.

Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

Eloot S, Van Biesen W, Roels S, Delrue W, Schepers E, Dhondt A, Vanholder R, Glorieux G.

PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.

24.

p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance.

Koppe L, Alix PM, Croze ML, Chambert S, Vanholder R, Glorieux G, Fouque D, Soulage CO.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2000-2009. doi: 10.1093/ndt/gfx089.

PMID:
28992089
25.

Further approaches to reduce the cost of renal replacement therapy.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Van Biesen W, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Nov;13(11):720. doi: 10.1038/nrneph.2017.136. Epub 2017 Sep 25. No abstract available.

PMID:
28944776
26.

Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Holvoet E, Glorieux G, Van Hoeck K, Van Dyck M, Godefroid N, Vanholder R, Roels S, Walle JV, Eloot S.

Pediatr Nephrol. 2018 Feb;33(2):315-323. doi: 10.1007/s00467-017-3802-5. Epub 2017 Sep 22.

PMID:
28939943
27.

The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.

Van Biesen W, Vanholder R, Schepers E, Glorieux G, Dhondt A, Eloot S.

Contrib Nephrol. 2017;191:168-177. doi: 10.1159/000479265. Epub 2017 Sep 14. Review.

PMID:
28910800
28.

Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial.

Van Laecke S, Caluwe R, Huybrechts I, Nagler EV, Vanholder R, Peeters P, Van Vlem B, Van Biesen W.

Ann Transplant. 2017 Aug 29;22:524-531.

29.

Hyponatraemia diagnosis and treatment clinical practice guidelines.

Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, van Biesen W, Nagler E, Gonzalez-Espinoza L, Ortiz A; Hyponatraemia Guideline Development Group.

Nefrologia. 2017 Jul - Aug;37(4):370-380. doi: 10.1016/j.nefro.2017.03.021. Epub 2017 Jun 12. English, Spanish.

30.

Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Biesen WV, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Jul;13(7):393-409. doi: 10.1038/nrneph.2017.63. Epub 2017 May 30. Review.

PMID:
28555652
31.

Early and asymptomatic cardiac dysfunction in chronic kidney disease.

Chinnappa S, White E, Lewis N, Baldo O, Tu YK, Glorieux G, Vanholder R, El Nahas M, Mooney A.

Nephrol Dial Transplant. 2018 Mar 1;33(3):450-458. doi: 10.1093/ndt/gfx064.

32.

"Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia.

Vanholder R.

Toxins (Basel). 2017 May 18;9(5). pii: E170. doi: 10.3390/toxins9050170.

33.

The systemic nature of CKD.

Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA).

Nat Rev Nephrol. 2017 Jun;13(6):344-358. doi: 10.1038/nrneph.2017.52. Epub 2017 Apr 24. Review.

PMID:
28435157
34.

Urea and chronic kidney disease: the comeback of the century? (in uraemia research).

Vanholder R, Gryp T, Glorieux G.

Nephrol Dial Transplant. 2018 Jan 1;33(1):4-12. doi: 10.1093/ndt/gfx039. Review.

PMID:
28407121
35.

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C.

Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640. doi: 10.1093/ndt/gfw433. Review.

PMID:
28340239
36.

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, Halimi JM, Heine G, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verharr MC, Wiecek A, Wuerzner G, London GM, Zoccali C.

J Hypertens. 2017 Apr;35(4):657-676. doi: 10.1097/HJH.0000000000001283.

PMID:
28157814
37.

p-Cresyl Sulfate.

Gryp T, Vanholder R, Vaneechoutte M, Glorieux G.

Toxins (Basel). 2017 Jan 29;9(2). pii: E52. doi: 10.3390/toxins9020052. Review.

38.

Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study.

Boelaert J, Lynen F, Glorieux G, Schepers E, Neirynck N, Vanholder R.

Anal Bioanal Chem. 2017 Mar;409(8):2201-2211. doi: 10.1007/s00216-016-0165-x. Epub 2017 Jan 12.

PMID:
28083662
39.

Chronic kidney disease.

Delles C, Vanholder R.

Clin Sci (Lond). 2017 Feb 1;131(3):225-226. doi: 10.1042/CS20160624. No abstract available.

PMID:
28057893
40.

Type 2 diabetes: a two-headed snake in kidney transplant recipients?

Van Laecke S, Vanholder R.

Lancet Diabetes Endocrinol. 2017 Jan;5(1):3-5. doi: 10.1016/S2213-8587(16)30404-1. No abstract available.

PMID:
28010786
41.

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.

43.

HEMO Revisited: Why Kt/Vurea Only Tells Part of the Story.

Meijers B, Vanholder R.

J Am Soc Nephrol. 2016 Nov;27(11):3235-3237. Epub 2016 Jun 7. No abstract available.

44.

Statins for the prevention of contrast-induced acute kidney injury.

Vanmassenhove J, Vanholder R, Lameire N.

Curr Opin Nephrol Hypertens. 2016 Nov;25(6):508-517. Review.

PMID:
27454753
45.

New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma.

Pavlenko D, van Geffen E, van Steenbergen MJ, Glorieux G, Vanholder R, Gerritsen KG, Stamatialis D.

Sci Rep. 2016 Oct 5;6:34429. doi: 10.1038/srep34429.

46.

Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study.

De Corte W, Dhondt A, Vanholder R, De Waele J, Decruyenaere J, Sergoyne V, Vanhalst J, Claus S, Hoste EA.

Crit Care. 2016 Aug 12;20(1):256. doi: 10.1186/s13054-016-1409-z.

47.

Acute kidney injury in critically ill cancer patients: an update.

Lameire N, Vanholder R, Van Biesen W, Benoit D.

Crit Care. 2016 Aug 2;20(1):209. doi: 10.1186/s13054-016-1382-6. Review.

48.

A urinary proteome-based classifier for the early detection of decline in glomerular filtration.

Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJL, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1510-1516. doi: 10.1093/ndt/gfw239.

PMID:
27387473
49.

Epidemiology of acute kidney injury in children worldwide, including developing countries.

Lameire N, Van Biesen W, Vanholder R.

Pediatr Nephrol. 2017 Aug;32(8):1301-1314. doi: 10.1007/s00467-016-3433-2. Epub 2016 Jun 15. Review.

PMID:
27307245
50.

The cell cycle biomarkers: promising research, but do not oversell them.

Lameire N, Vanmassenhove J, Van Biesen W, Vanholder R.

Clin Kidney J. 2016 Jun;9(3):353-8. doi: 10.1093/ckj/sfw033. Epub 2016 May 24. Review.

Supplemental Content

Loading ...
Support Center